| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING & TAX PREPARATION FEES | 16,253 | 0 | 16,253 |
| Category | Amount |
|---|---|
| 149 MEDICAL - BOLTON, MA UNSECURED CONVERTIBLE PROMISSORY NOTE | 150,000 |
| BIOROSA TECHNOLOGIES - BELMONT, MA UNSECURED CONVERTIBLE PROMISSORY NOTE | 150,000 |
| Grantee's Name | Grantee's Address | Grant Date | Grant Amount | Grant Purpose | Amount Expended By Grantee | Any Diversion By Grantee? | Dates of Reports By Grantee | Date of Verification | Results of Verification |
|---|---|---|---|---|---|---|---|---|---|
|
NONINVASIX INC |
1700 THE STRAND SUITE 1200 GALVESTON,TX77555 |
2017-07-27 | 7,000 | TO FUND NONINVASIX'S PARTICIPATION IN THE PHILIPS' MATERNAL AND INFANT HEALTHWORKS START-UP PROGRAM. | 7,000 | NONE, SEE BELOW | PRI REPORTS - 04/16/2020, 07/31/2020, 10/30/2020, 02/18/2021 | 2017-12-15 | THE TRUSTEES MEET WITH NONIVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
BREEGI SCIENTIFIC INC |
120 BEDFORD ROAD WOBURN,MA01801 |
2017-06-26 | 250,000 | THE FUNDS WILL BE USED TO CONDUCT A THOROUGH CLINICAL ASSESSMENT OF BSI'S NOVEL NEONATAL INTENSIVE CARE INCUBATOR "(NICI)" IN HONDURAS AND ZAMBIA AND TO AID THE COMMERCIALIZATION EFFORTS OF THIS LIFE-SAVING MEDICAL DEVICE. | 250,000 | NONE, SEE BELOW | PRI REPORTS - 03/19/2020, 09/14/2020, 08/02/2021, 08/12/2021 | 2021-08-02 | THE TRUSTEES MEET WITH BREEGI SCIENTIFIC, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
NONINVASIX INC |
1700 THE STRAND SUITE 1200 GALVESTON,TX77555 |
2015-12-30 | 150,000 | TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT. | 150,000 | NONE, SEE BELOW | PRI REPORTS - 04/16/2020, 07/31/2020, 10/30/2020, 02/18/2021 | 2017-12-15 | THE TRUSTEES MEET WITH NONIVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
ALDATU BIOSCIENCES INC |
C/O ARSENAL LAB SPACE 201 DEXTER AVE WATERTOWN,MA02472 |
2016-02-23 | 100,000 | TO SUPPORT THE USE AND DEVELOPMENT OF A SIMPLE, RAPID, THERMOSTABLE KIT THAT IDENTIFIES CLINICALLY ACTIONABLE HIV MUTATIONS FOUND IN PATIENTS FAILING A FIRST-LINE DRUG REGIMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED. | 100,000 | NONE, SEE BELOW | PRI REPORTS - 04/15/2020, 05/19/2021, 05/25/2021 | 2017-12-15 | THE TRUSTEES MEET WITH ALDATU BIOSCIENCES, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY. |
|
NONINVASIXINC |
1700 THE STRAND SUITE 1200 GALVESTON,TX77555 |
2016-07-27 | 150,000 | TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT. | 150,000 | NONE, SEE BELOW | PRI REPORT - 04/16/2020, 07/31/2020, 10/30/2020, 02/18/2021 | 2017-12-15 | THE TRUSTEES MEET WITH NONIVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
THINKMD INC |
166 MAIN STREET BURLINGTON,VT05401 |
2018-05-17 | 150,000 | FOR DEVELOPING INTEGRATED CLINICAL ASSESSMENT AND DATA ANALYTICS PLATFORMS AND OTHER DERIVATIVE PRODUCTS THAT TRANSFORM POINT-OF-CARE MEDICINE BY PUTTING VALIDATED CLINICAL ASSESSMENT CAPABILITY AND INCREASED HEALTHCARE KNOWLEDGE INTO THE HANDS OF CLINICALLY UNTRAINED HEALTHCARE PROFESSIONALS AND FAMILIES. | 150,000 | NONE, SEE BELOW | PRI REPORTS - 04/16/2020, 08/18/2020, 02/18/2021, 05/17/2021 | 2019-02-11 | THE TRUSTEES MEET WITH THINKMD, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY. |
|
PRAPELA LLC |
2 MAIN STREET BIDDEFORD,ME04005 |
2018-07-02 | 250,000 | THE PROCEEDS OF THE SALE AND ISSUANCE OF THE NOTES SHALL BE USED ONLY TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") - A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN. | 250,000 | NONE, SEE BELOW | PRI REPORTS - 09/10/2020, 06/02/2021 | 2020-09-10 | THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY. |
|
STINGRAY THERAPEUTICS |
2450 HOLCOMBE BLVD SUITE X HOUSTON,TX77021 |
2019-04-08 | 250,000 | FUNDS WILL BE USED FOR PRECLINICAL WORK FOCUSED ON PEDIATRIC BRAIN CANCERS, INCLUDING WORK TO DEVELOP PRECLINICAL MODELS AND TO TEST COMPOUNDS AGAINST MEDULLOBLASTOMA, TO TEST BLOOD BRAIN BARRIER PENETRATION, TO TEST WHETHER BLOOD BRAIN BARRIER PENETRATION IS EVEN NEEDED, AND IN PARALLEL, TO DO THE REGULATORY STUDIES REQUIRED TO FILE AN IND TO STUDY IN A PHASE 1-2 CLINICAL SETTING AND THE DRUG SUBSTANCE AND DRUG PRODUCT DEVELOPMENT AND MANUFACTURING REQUIRED FOR, AND TO BE USED SOLELY FOR THE PURPOSES OF, CLINICAL STUDY. | 250,000 | NONE, SEE BELOW | PRI REPORTS - 1/19/20, 7/15/20, 8/27/20, 10/7/20, 1/22/21, 4/15/21, 5/18/21 | 2021-05-18 | THE TRUSTEES MEET WITH STINGRAY THERAPEUTICS MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY. |
|
149 MEDICAL INC |
1173 MAIN STREET BOLTON,MA01740 |
2020-04-17 | 150,000 | TO SUPPORT THE PRE-COMMERCIALIZATION DEVELOPMENT OF A MONITOR THAT MEASURES REAL-TIME BRAIN HEMODYNAMICS AND METABOLISM IN PRETERM NEWBORNS, IN AN ATTEMPT TO CHANGE THE STANDARD OF CARE BY IMPROVING LIVES, REDUCING MEDICAL ERRORS, AND REDUCING OVERALL HEALTHCARE COSTS, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT. | 145,921 | NONE, SEE BELOW | PRI REPORT - 04/27/2020, 07/27/2020, 12/10/2020, 06/08/2021 | 2021-06-08 | THE TRUSTEES MEET WITH 149 MEDICAL, INC. ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
ANIDA PHARMA INC |
155 BROOKLINE STREET SUITE 005 CAMBRIDGE,MA02139 |
2020-12-21 | 250,000 | TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A PREVENTATIVE TREATMENT FOR RETINOPATHY OF PREMATURITY, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED. | 40,000 | NONE, SEE BELOW | PRI REPORT - 12/31/2020 | 2021-05-24 | THE TRUSTEES MEET WITH ANIDA PHARMA, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
BIOROSA TECHNOLOGIES INC |
63 BAKER STREET BELMONT,MA02478 |
2020-07-15 | 150,000 | TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT. | 150,000 | NONE, SEE BELOW | PRI REPORTS - 02/04/2021, 06/17/2021 | 2021-07-16 | THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
|
MESENTECH INC |
2222 HEALTH SCIENCES RD VANCOUVER,BRITISH COLUMBIAV6T2B9 CA |
2020-11-02 | 250,000 | TO SUPPORT THE ADVANCEMENT OF SCIENCE AND PROMOTION OF HEALTH THROUGH THE PRECLINICAL RESEARCH OF ANABOLIC BONE THERAPEUTICS THAT CAN INCREASE BONE MASS TO STRENGTHEN THE SKELETON AND THE DEVELOPMENT OF A DRUG DELIVERY SYSTEM TO BE INITIALLY APPLIED TO TWO PEDIATRIC RARE DISEASES: OSTEOGENESIS IMPERFECTA AND DUCHENNE MUSCULAR DYSTROPHY. | 80,755 | NONE, SEE BELOW | PRI REPORT - 05/18/2021 | 2021-05-18 | THE TRUSTEES MEET WITH MESENTECH, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY |
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| FIXED INCOME | 15,513,323 | 15,513,323 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| DOMESTIC EQUITIES | 36,997,735 | 36,997,735 |
| FOREIGN SECURITIES | 14,983,000 | 14,983,000 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| REAL ESTATE | FMV | 2,863,191 | 2,863,191 |
| ALTERNATIVE INVESTMENTS | FMV | 602,701 | 602,701 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| LEGAL EXPENSES | 28,703 | 0 | 28,703 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| PROGRAM RELATED INVESTMENTS | 1,307,000 | 2,119,964 | 2,119,964 |
| Description | Amount |
|---|---|
| LOSS ON INVESTMENT IN GPG HEALTHCARE OPPORTUNITIES FUND, LLC | 29,753 |
| LOSS ON INVESTMENT IN NEWBURY EQUITY PARTNERS V L.P. | 22,253 |
| LOSS ON INVESTMENT IN ACCOLADE PARTNERS VIII, L.P. | 8,569 |
| LOSS ON RCP FUND XIV CAYMAN FEEDER, LP | 55,783 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FILING FEES | 1,039 | 0 | 1,039 | |
| MISCELLANEOUS EXPENSES | 5,670 | 0 | 5,669 | |
| HRIA ADMINISTRATIVE COSTS | 131,820 | 0 | 131,821 | |
| PROGRAM RELATED INVESTMENT ADMINISTRATIVE COSTS | 7,404 | 0 | 7,404 | |
| MARKETING | 851 | 0 | 851 | |
| HONORARIA | 21,238 | 0 | 21,238 | |
| SCIENTIFIC ADVISORS | 42,742 | 0 | 42,742 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| RETURNED GRANT FUNDS | 175,535 | 175,535 | |
| MISCELLANEOUS INCOME | 4,479 | 4,479 |
| Description | Amount |
|---|---|
| UNREALIZED GAINS | 6,877,676 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT FEES - US TRUST | 31,525 | 15,762 | 15,763 | |
| INVESTMENT CONSULTING | 75,000 | 75,000 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAXES | 36,521 | 36,521 | 0 |